VBIOValion Bio, Inc.同业对比
Valion Bio, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VBIO本股 | $12M#8 | — | 2.8x#12 | 15.2x#7 | -33.7%#8 | -57.0%#11 | -1012.6%#7 | -209.1%#10 | — | — | -99.1%#3 | — |
| RKTO | $13M#1 | — | 1.6x#10 | — | — | -52.3%#10 | — | -152.0%#6 | — | — | — | — |
| BFRI | $13M#2 | — | 2.1x#11 | 0.3x#1 | 11.7%#5 | 40.7%#4 | -27.2%#2 | -176.9%#7 | -712.4%#5 | — | — | — |
| KTTA | $13M#3 | — | 0.3x#1 | 26.1x#9 | 3130.4%#2 | -46.9%#9 | -4286.7%#10 | -41.0%#2 | — | — | — | — |
| BOLT | $13M#4 | — | 1.0x#6 | 1.6x#4 | 0.1%#7 | 47.1%#3 | -469.3%#4 | -264.1%#13 | — | — | — | — |
| KAPA | $13M#5 | — | 3.0x#13 | — | — | -109.3%#12 | — | -130.0%#5 | — | — | — | — |
| HIND | $12M#6 | 0.0x#1 | 4.9x#14 | 38.6x#10 | 24.4%#3 | -609.0%#14 | -3269.4%#9 | -405.7%#15 | -226.2%#4 | — | — | — |
| LPCN | $12M#7 | — | 0.5x#4 | 6.0x#5 | -82.3%#10 | -96400.0%#16 | -524.7%#5 | -44.2%#3 | -52.6%#1 | — | — | — |
| PPCB | $12M#9 | — | 1.2x#8 | — | — | 68.0%#1 | — | -200.6%#8 | -176.3%#3 | — | — | — |
| CLRB | $11M#10 | — | 0.4x#2 | — | — | 51.1%#2 | — | -72.9%#4 | — | — | — | — |
| ASBP | $11M#11 | 0.0x#2 | 1.0x#5 | 1834.0x#11 | — | -1768.9%#15 | -312016.9%#11 | -208.2%#9 | — | — | — | — |
| SBFM | $11M#12 | 0.5x#3 | 0.4x#3 | 0.3x#2 | 4.1%#6 | -16.4%#7 | -17.2%#1 | -21.7%#1 | -63.1%#2 | — | — | — |
| BIVI | $11M#13 | — | 1.0x#7 | — | — | -25.8%#8 | — | -214.9%#11 | -1671.2%#6 | — | — | — |
| LIPO | $11M#14 | — | 7.1x#15 | 19.8x#8 | 19.3%#4 | -8.6%#6 | -947.2%#6 | -337.2%#14 | — | — | — | — |
| DARE | $11M#15 | — | — | 10.3x#6 | 10429.4%#1 | -230.9%#13 | -1315.5%#8 | — | — | — | -64.2%#1 | — |
| TVRD | $11M#16 | — | 1.3x#9 | 1.5x#3 | -66.0%#9 | 38.1%#5 | -374.8%#3 | -217.3%#12 | — | — | -83.0%#2 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-02。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议